U bent hier: Home > J Cannabis Ther > Combined Treatment of Tourette Syndrome with Delta-9-THC and Dopamine Receptor Antagonists
J Cannabis Ther 2002(3/4):143-152
Tourette Syndrome
Combined Treatment of Tourette Syndrome with Delta-9-THC and Dopamine Receptor Antagonists
Author
KR Müller-Vahl, U Schneider, HM Emrich
Abstract
Animal studies suggest that cannabinoid receptor agonists might enhance the effect of dopamine receptor antagonists (neuroleptics, NL) in hyperkinetic movement disorders. In Tourette syndrome, NL are the most effective drugs for the treatment of tics. Recent clinical trials demonstrated that delta-9-tetrahydrocannabinol (delta-9-THC) also produces a tic-suppressing effect. In this single case study in a 24 years old female suffering from TS with extreme tics, it is suggested for the first time that delta-9-THC may be useful in augmenting the pharmacological response to atypical NL such as amisulpride and risperidone in TS patients. No serious adverse reactions occurred. Controlled studies are necessary to confirm this initial report.
Keywords
Tourette syndrome, tics, cannabis, THC, amisulpride, neuroleptics
IACM Conference 2019
The IACM Conference 2019 will be held on October 31 - November 2, 2019, at Estrel Hotel, Berlin, Germany.
Ondersteunde conferenties
STCM Conference, 19 January 2019, University Hospital Bern, Switzerland
Cann10, 14-16 October 2018, Tel Aviv Israel.
Members only
IACM on Twitter
Follow us on twitter @IACM_Bulletin where you can send us inquiries and receive updates on research studies and news articles.